Progress in the treatment of pulmonary fibrosis

Affiliations

¹ Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre Rotterdam, 3015 GD Rotterdam, Netherlands. Electronic address: m.wijsenbeek-lourens@erasmusmc.nl.

Comment

Marlies Wijsenbeek. Lancet Respir Med. 2020 May.

. 2020 May;8(5):424-425.

doi: 10.1016/S2213-2600(20)30062-X. Epub 2020 Mar 5.

¹ Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre Rotterdam, 3015 GD Rotterdam, Netherlands. Electronic address: m.wijsenbeek-lourens@erasmusmc.nl.

No abstract available

Comment on

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.